TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37184136
Drug: Izokibep, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Izokibep, a novel IL-17A neutralizing Affibody molecule, dosage and duration not specified
Study: 37184523
Drug: Maralixibat ≤10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat ≤10 mg/d for 14 weeks
Study: 37184615
Drug: Group-based acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based acceptance and commitment therapy to address self-stigma
Study: 37184839
Drug: Esmolol 14%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 14% gel with standard of care (SoC)
Study: 37184839
Drug: Esmolol 14%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 14% gel with SoC
Study: 37184872
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU).
Study: 37185193
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of levothyroxine treatment after a control period of 12 weeks, with gradual discontinuation and regular monitoring of thyroid function.
Study: 37185193
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period of 12 weeks with continuous levothyroxine treatment.
Study: 37185197
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous remimazolam
Study: 37185903
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (sending glucose readings via smartphone application and monthly video calls)
Study: 37185903
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (routine monthly on-site visits)
Study: 37186063
Drug: Binimetinib 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib 45 mg orally twice daily (bid) with Hydroxychloroquine 400 mg orally bid
Study: 37186094
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at incremental rates up to 1.0 μg/kg/min
Study: 37186094
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of phenylephrine infusion
Study: 37186265
Drug: Intranasal GnRH-agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal GnRH-agonist
Study: 37186357
Drug: Transabdominal electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transabdominal electrical stimulation by interferential therapy (IFT)
Study: 37187198
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (3 mg/m2)
Study: 37187198
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (idarubicin, cytarabine, etoposide, ATRA)
Study: 37187201
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy
Study: 37187863
Drug: e-CBT (online
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-CBT (online cognitive behavioral therapy)
Study: 37187878
Drug: Leucine-enriched amino
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-enriched amino acid supplementation (6 g per day for 12 weeks)
Study: 37188177
Drug: Patient empowerment
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient empowerment program including educational workshops and videos about mBC and precision medicine
Study: 37188309
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (twice a week for 8 weeks, 50 min each session)
Study: 37188668
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks
Study: 37188783
Drug: Intratumoral delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD-1 antibody pembrolizumab
Study: 37188895
Drug: napabucasin (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: napabucasin (480 mg/day) plus sorafenib (800 mg/day)
Study: 37189075
Drug: First-line pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line pembrolizumab plus chemotherapy in treatment-naïve LCC (n=27)
Study: 37189075
Drug: First-line pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line pembrolizumab plus chemotherapy in treatment-naïve LCNEC (n=10)
Study: 37189075
Drug: Subsequent-line pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent-line pembrolizumab with or without chemotherapy in pre-treated LCC (n=23)
Study: 37189075
Drug: Subsequent-line pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent-line pembrolizumab with or without chemotherapy in pre-treated LCNEC (n=23)
Study: 37189085
Drug: Normal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal treatment
Study: 37189171
Drug: Novel medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel medication alerts encouraging collaboration between prescribers and expert pharmacists in anticoagulation clinics.
Study: 37189171
Drug: Existing prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing prescription notifications for inappropriate DOACs.
Study: 37189190
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Summer Camp and Parent Intervention (SCV+PI)
Study: 37190665
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus upper limb robot-assisted therapy (UL-RAT) using an exoskeleton robotic system (Armeo)
Study: 37190883
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone-marrow-derived mononuclear cells with Impella CP device support
Study: 37190970
Drug: Digital solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital solution (Noona)
Study: 37190970
Drug: Digital solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital solution
Study: 37191154
Drug: High-intensity care
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity care (HIC) strategy of guideline-directed medical therapies (GDMT) up-titration
Study: 37191188
Drug: Arginine methylation
Normalized name: methyl L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine methylation inhibitors
Study: 37192040
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 120 mg
Study: 37192040
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 180 mg
Study: 37192040
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 240 mg
Study: 37192282
Drug: Prompted self-measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompted self-measured blood pressure monitoring and feedback (weekly)
Study: 37192282
Drug: Prompted self-measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompted self-measured blood pressure monitoring and feedback (daily)
Study: 37192288
Drug: Cardiac scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac scale measurements (daily)
Study: 37192754
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion to increase mean arterial blood pressure (MAP) by a maximum of 30 mmHg to an absolute level of no more than 130 mmHg.
Study: 37192754
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion to increase MAP.
Study: 37194068
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing of follitropin delta (average daily dose 11.0 ± 1.6 µg, duration 10.3 ± 1.6 days)
Study: 37194068
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing of follitropin delta
Study: 37194074
Drug: Group well
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group well child care provided on-site at a maternal substance use disorder treatment program.
Study: 37194394
Drug: Brepocitinib 30
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brepocitinib 30 mg once daily
Study: 37194394
Drug: Brepocitinib 60
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brepocitinib 60 mg once daily
Study: 37194394
Drug: Brepocitinib 30
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brepocitinib 30 mg and 60 mg once daily
Study: 37194458
Drug: Preoperative hyper-polypharmacy
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative hyper-polypharmacy (greater than or equal to 10 medications)
Study: 37194458
Drug: Preoperative polypharmacy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative polypharmacy (5-9 medications)
Study: 37194458
Drug: Non-polypharmacy (fewer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-polypharmacy (fewer than 5 medications)
Study: 37194488
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) 1.5 mg/kg intravenous infusion, administered 15 minutes prior to surgery
Study: 37194813
Drug: Medium intensity
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium intensity coughing technique during subcutaneous low molecular weight heparin injection
Study: 37195023
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ONC201 and paxalisib
Study: 37195128
Drug: ICI combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI combined with chemotherapy
Study: 37195423
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) monotherapy after ultra-short-pulse glucocorticoids (GCs)
Study: 37195666
Drug: Deliberate practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deliberate practice intervention (3 weekly, 30-minute video-conferenced sessions with personalized feedback)
Study: 37195667
Drug: SIB-RT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIB-RT with concurrent and consolidated oral S-1 chemotherapy (CRTCT group)
Study: 37195941
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg of peresolimab
Study: 37196061
Drug: PXVX0317 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXVX0317 vaccine
Study: 37196069
Drug: Hypofractionated stereotactic
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated stereotactic radiotherapy (hFSRT) combined with 1500 mg Durvalumab on day 5, followed by infusions every 4 weeks for up to 12 months.
Study: 37196396
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure (PAP) treatment for OSAS
Study: 37196527
Drug: Metarrestin (ML-246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metarrestin (ML-246) administered orally at a dose of 1 mg
Study: 37197905
Drug: Test, treat,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test, treat, retest and re-treat initial treatment failures
Study: 39666396
Drug: NVX-CoV2373 booster
Normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 booster dose
Study: 37199326
Drug: Pembrolizumab combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab combined with quad-shot radiotherapy (14.8 Gy in four twice-daily fractions)
Study: 37199427
Drug: Maternal tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maternal tenofovir disoproxil fumarate-based antiretroviral treatment (mART)
Study: 37199438
Drug: Hip Fracture
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip Fracture Injection (HiFI) - multimodal local injection of bupivacaine, morphine sulfate, ketorolac at the fracture site during surgery
Study: 37199438
Drug: Hip Fracture
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip Fracture Injection (HiFI)
Study: 37199745
Drug: Fenretinide (4-HPR)
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide (4-HPR) 600 mg/m
Study: 37199745
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fenretinide plus safingol
Study: 37199884
Drug: Upadacitinib (UPA)
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib (UPA) 6 mg BID, titrated to 12 mg BID if necessary, later replaced by 15/30 mg once-daily extended-release equivalents
Study: 37200944
Drug: High energy-dense
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy-dense oral nutritional supplement (edONS, 2.4 kcal/mL)
Study: 37200944
Drug: Reference oral
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference oral nutritional supplement (heONS, 2.0 kcal/mL)
Study: 37201438
Drug: Remotely delivered,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotely delivered, individualized, and self-directed gait modification with weekly telerehabilitation appointments and remote monitoring
Study: 37201546
Drug: Immediate Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Sequential Bilateral Cataract Surgery (ISBCS)
Study: 37201546
Drug: Delayed Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Sequential Bilateral Cataract Surgery (DSBCS)
Study: 37201747
Drug: M-TAPA (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-TAPA (40 ml 0.25% bupivacaine)
Study: 37201756
Drug: Preoperative Proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Proton Beam Therapy with Concurrent Chemotherapy
Study: 37201900
Drug: Ketamine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine intravenous therapy (KIT) induction
Study: 37201900
Drug: Ketamine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine intravenous therapy (KIT) maintenance
Study: 37201900
Drug: Ketamine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine intravenous therapy (KIT) at eight weeks
Study: 37202039
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy received in the first days of intensive care admission
Study: 37202042
Drug: ω-3 fatty
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 fatty acid ethyl esters (4 g/day)
Study: 37202073
Drug: Semi-elemental enteral
Normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-elemental enteral formula with partially hydrolyzed guar gum (PHGG) at 12 g/L
Study: 37202530
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega 3 supplement (40 mg/kg/day) for 2 weeks
Study: 37202813
Drug: Dapagliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (5 mg p.o./day for 2 weeks escalated to 10 mg p.o./day for 6 weeks)
Study: 37202822
Drug: TAPER (team
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAPER (team approach to polypharmacy evaluation and reduction)
Study: 37203207
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gas in fistula and clinical finding of fluid discharge through the external fistula opening at 3 months
Study: 37204106
Drug: INO-3107 administered
Normalized name: INO
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INO-3107 administered by intramuscular injection followed by electroporation on weeks 0, 3, 6, and 9.
Study: 37205012
Drug: Direct-to-implant (DTI)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-to-implant (DTI)
Study: 37205592
Drug: Bivalent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters (Moderna mRNA-1273, Pfizer-BioNTech BNT162b2, Sanofi CoV2 preS DTM-AS03)
Study: 37205592
Drug: Prototype/Wildtype Vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype/Wildtype Vaccines
Study: 37205721
Drug: IDA1 (ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDA1 (ivermectin 150 μg/kg + albendazole 400 mg + diethylcarbamazine 6 mg/kg)
Study: 37205721
Drug: IDA3 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDA3 (three consecutive daily doses of IDA)
Study: 37205721
Drug: IA (ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA (ivermectin 150 μg/kg + albendazole 400 mg)
Study: 37205721
Drug: IDA treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDA treatments (both IDA1 and IDA3 combined)
Study: 37206279
Drug: GS-0189 as
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-0189 as monotherapy and in combination with rituximab
Study: 37206996
Drug: CT-STAR (cone-beam
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-STAR (cone-beam computed tomography-guided stereotactic adaptive radiation therapy)
Study: 37207143
Drug: Vanucizumab in
Normalized name: Vanucizumab
DrugBank: Vanucizumab (DB12317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanucizumab in combination with mFOLFOX-6 chemotherapy
Study: 37207143
Drug: Bevacizumab (VEGF-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (VEGF-A inhibitor) in combination with mFOLFOX-6 chemotherapy
Study: 37207300
Drug: Switched endocrine
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched endocrine therapy (fulvestrant or exemestane) plus ribociclib
Study: 37207300
Drug: Switched endocrine
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched endocrine therapy (fulvestrant or exemestane) plus placebo
Study: 37207382
Drug: Eteplirsen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eteplirsen (30 mg/kg, once-weekly intravenously for 10 weeks, continuing at 30 mg/kg up to 96 weeks)
Study: 37207382
Drug: Eteplirsen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eteplirsen (30 mg/kg)
Study: 37207654
Drug: tislelizumab-chemotherapy
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tislelizumab-chemotherapy
Study: 38607538
Drug: placebo-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo-chemotherapy
Study: 37207655
Drug: PI3K inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI3K inhibitors (specifically alpelisib)
Study: 37207810
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure for 6 weeks
Study: 37208132
Drug: Projection-based augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Projection-based augmented reality exposure treatment system (P-ARET)
Study: 37208132
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo exposure treatment (IVET)
Study: 37208133
Drug: MK-7 (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7 (333 µg/day)
Study: 37208142
Drug: Projection-based AR
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Projection-based AR exposure therapy with multiple stimuli (P-ARET MS)
Study: 37208142
Drug: Projection-based AR
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Projection-based AR exposure therapy with a single stimulus (P-ARET SS)
Study: 37208431
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose 7.5 mg/kg
Study: 37208431
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose 15 mg/kg
Study: 37208556
Drug: Ponatinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib + steroids
Study: 37208556
Drug: Imatinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib monotherapy induction + imatinib-containing consolidation
Study: 37208675
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 2% lidocaine with epinephrine 1:200,000
Study: 37208675
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 2% lidocaine with epinephrine 1:200,000 plus 2 mL sodium bicarbonate 4.2% (total of 12 mL)
Study: 37209152
Drug: 50 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU/kg unfractionated heparin (UFH)
Study: 37209152
Drug: 100 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU/kg unfractionated heparin (UFH)
Study: 37209152
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg enoxaparin
Study: 37209152
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg enoxaparin
Study: 37209238
Drug: Interferon/ribavirin (prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon/ribavirin (prior treatment)